Studien & Berichte
30. Aug. 2026•1 Min. Lesezeit
LIGACEM BioScience Unveils LCB 2.0 R&D Strategy Targeting ADC Innovation and Next‑Gen Modalities
LIGACEM BioScience announced its LCB 2.0 R&D roadmap at Global R&D Day 2026, aiming to boost ADC innovation, expand into next‑generation modalities and accelerate high‑value technology transfer.
Studien & Berichte
30. Aug. 2026•1 Min. Lesezeit
LigaChem Bio Unveils Long-Term R&D Roadmap Focused on ADC Advancement and New Therapeutic Modalities
LigaChem Bio presented its 2035 R&D roadmap, aiming to enhance its ADC platform, explore non‑oncology indications and boost next‑generation drug success through patient‑centric research.